Valbiotis
Solutions for cardio-metabolic diseases prevention.
- biotechnology
- sustainable development goals
- dt and ls
- biotech and pharma
- radar de l'innovation
- risk management
- tech for business
- observatoire industrial tech
- observatoire deeptech
- nutrition
- cardiology and cardiovascular
- diabetes
- personal health
- food as medicine
- metabolism
- microbiology
- weight management
- agritech and foodtech
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 25 % | 31 % | 232 % | (53 %) | 31 % | 77 % | (96 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (500 %) | (319 %) | (54 %) | (367 %) | (420 %) | (135 %) | (5241 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (400 %) | (420 %) | (88 %) | (424 %) | (460 %) | (156 %) | (5729 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 100 % | 303 % | 124 % | 192 % | 189 % | 151 % | 2650 % |
Source: Company filings or news article
Related Content
Valbiotis is a research and development company focused on addressing metabolic diseases through scientific innovation. The company operates in the healthcare sector, targeting unmet medical needs with a pipeline of proprietary compounds, including TOTUM 63, TOTUM 070, TOTUM 854, and TOTUM 448. Valbiotis collaborates with global partners, such as HEALTH SCIENCE, to develop and commercialize its products. The business model revolves around advancing these compounds through clinical trials and securing strategic partnerships for commercialization. Valbiotis serves healthcare professionals, investors, and the general public, aiming to provide effective solutions for conditions like hypercholesterolemia and diabetes. The company generates revenue through partnerships and potential product sales upon successful market entry. Valbiotis actively participates in scientific events and publications to maintain its presence in the research community.